---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017015"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:56:57.041557+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics Q3 2022 net loss $19.8M; XTX202 reaches target dose; XTX301 IND cleared

## Summary
- Cash $139.1M as of Sep 30, 2022; runway into Q2 2024.
- Net loss $19.8M in Q3 2022 vs $16.3M in Q3 2021; R&D expense $13.0M.
- XTX202 (IL-2) dosed at target 1 mg/kg; no vascular leak syndrome; CD8+ T cell increases seen.
- FDA cleared IND for XTX301 (IL-12); Phase 1 start expected Q1 2023.
- Company will seek partner for XTX101 (anti-CTLA-4); will not initiate a Phase 2 alone.

## SEC filing metadata
- accession: 0001558370-22-017015
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/0001558370-22-017015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/xlo-20221109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017015
- JSON: https://secwatch.observer/filing/0001558370-22-017015.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017015.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/0001558370-22-017015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.